Ventyx Biosciences, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	S-1/A
Revenues	0.0	87.7	0.0	58.5	0.0	3.6
Revenue growth		50.0%			-100.0%
Cost of goods sold	0.0	113.1	0.0	67.1	0.0	7.1
Gross profit	0.0	-25.4	0.0	-8.7	0.0	-3.6
Gross margin		-28.9%		-14.8%		-100.0%
Selling, general and administrative [+]	113.1	25.4	67.1	8.7	0.7	0.6
General and administrative		25.4		8.7	0.7	0.6
Research and development					6.4
Other operating expenses	-9.4	62.3	11.5	49.8		0.0
EBIT [+]	-103.7	-113.1	-78.7	-67.1	-7.1	-4.2
EBIT growth	31.9%	68.5%	1015.6%		68.7%
EBIT margin		-128.9%		-114.8%		-117.7%
Non-recurring items			21.7
Interest income, net [+]	4.7	4.7	0.1	0.0
Interest expense				0.1	0.4
Interest income	4.7	4.7	0.1	0.1	0.4
Other income (expense), net [+]	-9.4	0.0	16.5	-16.6	-21.1	-0.1
Unrealized gain (loss) on marketable securities		-1.0		-0.1
Other		0.0		-0.1	0.0
Pre-tax income	-108.4	-108.4	-83.7	-83.7	-28.2	-4.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-108.4	-0.1	-83.7	-0.1	-28.2	0.0
Net margin		-0.1%		-0.1%		-0.1%

Basic EPS [+]	($2.07)	($2.07)	($6.53)	($6.65)	($14.17)	($2.60)
Growth	-68.4%	-68.9%	-53.9%		444.1%
Diluted EPS [+]	($2.07)	($2.07)	($6.53)	($6.65)	($14.17)	($2.60)
Growth	-68.4%	-68.9%	-53.9%		444.1%

Shares outstanding (basic) [+]	52.5	0.1	12.8	0.0	2.0	0.0
Growth	309.1%	309.1%	545.0%		119561.4%
Shares outstanding (diluted) [+]	52.5	0.1	12.8	0.0	2.0	0.0
Growth	309.1%	309.1%	545.0%		119561.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.